The antiphospholipid story

Journal of Rheumatology

Volumn 30, Issue 9, 2003, Pages 1893-1896

  Alarcón Segovia, Donato ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; EPITOPE; INTERLEUKIN 6; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLEEDING; COHORT ANALYSIS; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTORY OF MEDICINE; HUMAN; LABORATORY DIAGNOSIS; LIVEDO RETICULARIS; MOLECULAR MIMICRY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENT ABORTION; SKIN ULCER; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOPHLEBITIS; THROMBOSIS;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INCIDENCE; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 0043195847     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (49)

1. Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche reaktion bei syphilis. Dtsch Med Wochenschr 1906;32:745-9.
2. Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exper Biol Med 1941;48:484-6.
3. Moore JE, Lutz WB. Natural history of systemic lupus erythematosus: approach to its study through chronic biologic false positive reactors. J Chron Dis 1955;1:297-316.
4. Hargraves MM, Richmond H, Morton R. Presentation of 2 bone marrow elements: the "Tart" cell and the "LE" cell. Proc Staff Meet Mayo Clin 1948;23:25-8.
5. Dubois EL. Effect of LE cell on clinical picture of systemic lupus erythematosus. Ann Intern Med 1953;93:1265-94.
6. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Lab Clin Invest 1952;31:621-2.
7. Sánchez-Medal L, Lisker R. Circulating anticoagulants in disseminated lupus erythematosus. Br J Haematol 1959;5:284-93.
8. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-30.
9. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb 1972;1:75-95.
10. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of lupus anticoagulant. J Clin Invest 1980;66:397-405.
11. Alarcón-Segovia D, Osmundson PJ. Peripheral vascular syndromes associated with systemic lupus erythematosus. Ann Intern Med 1965;62:907-19.
12. Alarcón-Segovia D. Infarction and circulating anticoagulant. Lancet 1967;2:43-4.
13. Johansson EA, Lassus A. The occurrence of circulating anticoagulants in patients with syphilitic and biologically false positive antilipoidal antibodies. Ann Clin Res 1974;6:105-8.
14. Soulier JP, Boffa MC. Avortements á repetition, thromboses et anticoagulant circulant antithromboplastine. Nouv Presse Med 1980;9:859-64.
15. Carreras LO, Defreyn G, Machin SJ, et al. Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;i:244-6.
16. Smolarsky MA. A simple radioimmunoassay to determine binding of antibodies to lipid antigens. J Immunol Methods 1980;38:85-93.
17. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-4.
18. Loizou S, McCrea JD, Rudge A, Reynolds A, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985;62:738-45.
19. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985;3:285-6.
20. Delezé M, Oria CV, Alarcón-Segovia D. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol 1988;15:611-5.
21. Alarcón-Segovia D, Delezé M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
22. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-85.
23. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
24. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.
25. Asherson RA. A "primary" antiphospholipid syndrome? J Rheumatol 1988;15:1742-6.
26. Mackworth-Young CG, Loizou S, David J, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989;48:362-7.
27. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
28. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
29. McNeil HD, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
30. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
31. Shoenfeld Y, Meroni PL. The beta-2-glycoprotein I and antiphospholipid antibodies. Clin Exp Rheumatol 1992;10:205-9.
32. Viard JP, Amoura Z, Bach JF. Association of anti-beta2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-6.
33. Gómez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcón-Segovia D. Serum anti-beta 2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417-23.
34. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
35. Roubey RAS, Eisenberg R, Harper MF, Winfield JB. " Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954-60.
36. Cabiedes J, Cabral AR. Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in systemic lupus erythematosus patients associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22:1899-906.
37. Alarcon-Segovia D, Cabral AR. Antiphospholipid/cofactor syndromes. J Rheumatol 1996;23:1319-22.
38. Alarcon-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol 1988;15:890-3.
39. Ruiz-Arguelles GJ, Ruíz-Argüelles A, Alarcón-Segovia D, et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 1991;18:552-8.
40. Vazquez-Mellado J, Llorente L, Alarcón-Segovia D. Exposure of anionic phospholipid upon platelet activation permits binding of beta 2-glycoprotein-I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994;7:335-48.
41. Cabral AR, Cabiedes J, Alarcón-Segovia D. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J Autoimmun 1990;3:773-87.
42. Del Papa N, Meroni PL, Tincani A, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992;10:37-42.
43. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
44. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome by passive transfer of anti-cardiolipin antibodies. Proc Nat Acad Sci USA 1991;88:3069-73.
45. Blank M, Faden D, Tincani A, et al. Immunization with anticardiolipin cofactor (beta 2 GP-I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441-55.
46. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Nat Acad Sci USA 1999;96:5164-8.
47. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta 2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797-804.
48. Yoshida K, Arai T, Kaburaki J, Ikeda Y, Kawakami Y, Kuwana M. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002;99:2499-504.
49. Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis S. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. J Biol Chem 2002;277:1-6.